125 related articles for article (PubMed ID: 11605047)
1. Pharmacokinetics and pharmacodynamics of serum platinum of gynecologic cancer patients treated with nedaplatin.
Matsumoto Y; Ishiko O; Nakagawa E; Sumi T; Hyun Y; Ando Y; Ogita S
Oncol Rep; 2001; 8(6):1269-73. PubMed ID: 11605047
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
Niioka T; Uno T; Yasui-Furukori N; Takahata T; Shimizu M; Sugawara K; Tateishi T
Cancer Chemother Pharmacol; 2007 Apr; 59(5):575-80. PubMed ID: 16912889
[TBL] [Abstract][Full Text] [Related]
3. Cytocidal effect and DNA damage of nedaplatin in vitro by simulating pharmacokinetic parameters.
Kawanishi K; Miyagi Y; Yamamoto J; Miyagi Y; Nakamura K; Kodama J; Hongo A; Yoshinouchi M; Kudo T
Cancer Chemother Pharmacol; 2001 Apr; 47(4):303-8. PubMed ID: 11345646
[TBL] [Abstract][Full Text] [Related]
4. Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxicodynamic analysis.
Ishibashi T; Yano Y; Oguma T
Anticancer Res; 2005; 25(2B):1273-81. PubMed ID: 15865078
[TBL] [Abstract][Full Text] [Related]
5. A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients.
Ishibashi T; Yano Y; Oguma T
Cancer Chemother Pharmacol; 2002 Sep; 50(3):230-6. PubMed ID: 12203105
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetics of cis-diammine (glycolato) platinum (254-S), a new platinum antitumor agent, following an intravenous and intraperitoneal infusion bioactive platinum concentration profile].
Hirabayashi K; Okada E; Oguma T; Shimamura K
Gan To Kagaku Ryoho; 1990 Nov; 17(11):2221-7. PubMed ID: 2241186
[TBL] [Abstract][Full Text] [Related]
7. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of concurrent chemoradiation with weekly nedaplatin in patients with squamous cell carcinoma of the uterine cervix.
Yoshinaga K; Niikura H; Ogawa Y; Nemoto K; Nagase S; Takano T; Ito K; Yaegashi N
Gynecol Oncol; 2007 Jan; 104(1):36-40. PubMed ID: 16889822
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of oxaliplatin in gastrointestinal cancer patients with malignant ascites.
Kochi M; Fujii M; Kanamori N; Kaiga T; Okubo R; Mihara Y; Takayama T
J Chemother; 2011 Feb; 23(1):28-31. PubMed ID: 21482491
[TBL] [Abstract][Full Text] [Related]
10. Optimal sampling and limited sampling strategies for estimation of unbound platinum AUC after nedaplatin infusion.
Ishibashi T; Fukumura K; Yano Y; Oguma T
Anticancer Res; 2005; 25(2B):1283-9. PubMed ID: 15865079
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of platinum in cancer patients following intravenous infusion of cis-diammine(glycolato)platinum, 254-S.
Ota K; Oguma T; Shimamura K
Anticancer Res; 1994; 14(3B):1383-7. PubMed ID: 8067710
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin.
Figg WD; Christian MC; Lush R; Link CJ; Davis P; Kohn E; Sarosy G; Rothenberg ML; Weiss RB; Ryan N; Jacobs J; Reed E
Biopharm Drug Dispos; 1997 May; 18(4):347-59. PubMed ID: 9158882
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
14. Platinum concentrations in uterus and serum after internal iliac arterial infusion of platinum compounds in rabbits.
Kigawa J; Minagawa Y; Itamochi H; Kanamori Y; Ishihara H; Terakawa N
Obstet Gynecol; 1995 Aug; 86(2):265-8. PubMed ID: 7617358
[TBL] [Abstract][Full Text] [Related]
15. Local distribution into brain tumor and pharmacokinetics of 4-pyridoxate diammine hydroxy platinum, a novel cisplatin derivative, after intracarotid administration in rats with 9L malignant glioma: simultaneous brain microdialysis study.
Tokunaga Y; Nakashima M; Sasaki H; Tomiyama N; Nakashima MN; Ichikawa M; Kaminogo M; Shibata S
Biol Pharm Bull; 2000 Dec; 23(12):1491-6. PubMed ID: 11145184
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy.
Loh GW; Ting LS; Ensom MH
Clin Pharmacokinet; 2007; 46(6):471-94. PubMed ID: 17518507
[TBL] [Abstract][Full Text] [Related]
17. Initial analysis of relationship between plasma platinum concentration and hematological adverse reaction associated with weekly chemotherapy using nedaplatin in combination with radiotherapy for cervical carcinoma.
Hamada Y; Naitoh H; Niibe Y; Kotani A; Takayanagi R; Tsunoda S; Unno N; Hayakawa K; Kusu F; Yago K; Yamada Y
Eur J Gynaecol Oncol; 2010; 31(5):517-21. PubMed ID: 21061792
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
19. Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) .
Kim HT; Kim DK; Cho YB; Kim TS; Jung I; Kim KH; Heo DS; Bang YJ; Shin SG; Kim NK
Cancer Chemother Pharmacol; 1998; 41(2):109-16. PubMed ID: 9443623
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin.
Sasaki Y; Tamura T; Eguchi K; Shinkai T; Fujiwara Y; Fukuda M; Ohe Y; Bungo M; Horichi N; Niimi S
Cancer Chemother Pharmacol; 1989; 23(4):243-6. PubMed ID: 2647312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]